Shanghai Kaibao Pharmaceutical (300039) — Financial Flexibility Index
Shanghai Kaibao Pharmaceutical (300039) has a Financial Flexibility Index of 0.47x as of September 2025. Free cash flow of CN¥194.35 Million (operating CF CN¥190.98 Million minus capex CN¥3.37 Million) represents 0% of total liabilities (CN¥412.55 Million). Check Shanghai Kaibao Pharmaceutical total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shanghai Kaibao Pharmaceutical Financial Flexibility Index (2006–2025)
Historical Financial Flexibility Index trend for Shanghai Kaibao Pharmaceutical across 20 annual periods. For the full cash flow conversion analysis, see 300039 cash flow conversion.
Annual Financial Flexibility Index for Shanghai Kaibao Pharmaceutical (2006–2025)
Year-by-year free cash flow to debt coverage for Shanghai Kaibao Pharmaceutical. Explore cash flow to debt ratio of Shanghai Kaibao Pharmaceutical to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.72x | CN¥257.78 Million | CN¥230.74 Million | CN¥359.64 Million | ▼ -29.0% |
| 2024 | 1.01x | CN¥419.47 Million | CN¥278.95 Million | CN¥415.45 Million | ▲ +34.1% |
| 2023 | 0.75x | CN¥411.74 Million | CN¥382.66 Million | CN¥546.82 Million | ▼ -8.1% |
| 2022 | 0.82x | CN¥408.04 Million | CN¥376.42 Million | CN¥498.24 Million | ▲ +51.0% |
| 2021 | 0.54x | CN¥168.63 Million | CN¥126.08 Million | CN¥310.90 Million | ▼ -38.7% |
| 2020 | 0.89x | CN¥264.59 Million | CN¥250.65 Million | CN¥298.96 Million | ▼ -30.9% |
| 2019 | 1.28x | CN¥349.54 Million | CN¥334.09 Million | CN¥273.01 Million | ▲ +16.4% |
| 2018 | 1.10x | CN¥288.43 Million | CN¥262.36 Million | CN¥262.26 Million | ▲ +17.2% |
| 2017 | 0.94x | CN¥295.00 Million | CN¥245.76 Million | CN¥314.26 Million | ▼ -10.1% |
| 2016 | 1.04x | CN¥341.91 Million | CN¥314.88 Million | CN¥327.61 Million | ▲ +16.4% |
| 2015 | 0.90x | CN¥377.48 Million | CN¥327.08 Million | CN¥421.16 Million | ▼ -40.6% |
| 2014 | 1.51x | CN¥351.12 Million | CN¥282.38 Million | CN¥232.72 Million | ▼ -36.0% |
| 2013 | 2.36x | CN¥388.52 Million | CN¥270.23 Million | CN¥164.72 Million | ▲ +13.6% |
| 2012 | 2.08x | CN¥295.53 Million | CN¥243.32 Million | CN¥142.29 Million | ▲ +46.6% |
| 2011 | 1.42x | CN¥167.16 Million | CN¥98.31 Million | CN¥117.97 Million | ▲ +167.0% |
| 2010 | 0.53x | CN¥70.80 Million | CN¥19.79 Million | CN¥133.39 Million | ▼ -40.8% |
| 2009 | 0.90x | CN¥178.44 Million | CN¥52.74 Million | CN¥199.20 Million | ▲ +207.6% |
| 2008 | 0.29x | CN¥29.98 Million | CN¥18.70 Million | CN¥102.95 Million | ▼ -11.6% |
| 2007 | 0.33x | CN¥27.89 Million | CN¥23.27 Million | CN¥84.64 Million | ▼ -24.7% |
| 2006 | 0.44x | CN¥31.43 Million | CN¥19.70 Million | CN¥71.80 Million | — |